drugset / Trial / NCT03905707
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Timeline
- Start
- 2019-05-07
- Primary completion
- 2026-04
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glepaglutide | Peptide | 10 mg | Subcutaneous |